Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker DiscoveryBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda, which began in 2024. This extension leverages the Beacon Platform to accelerate data-driven development of sleep biomarkers and patterns, and supports new diagnostic pathways that close longstanding care gaps for people with narcolepsy. Under the terms of the agreement, Beacon is eligible to receive up to $109 million in data license fees and potential development, regulatory, and commercial-based milestones, including equity participation.
Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain HealthNew funding will expand Beacon’s precision medicine data platform, unlocking discoveries and treatments for neurological and psychiatric disease
Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual MeetingBOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, the global leader in at-home EEG and AI-powered brain health analytics, presented two scientific posters at the American Epilepsy Society (AES) Annual Meeting. These posters highlight groundbreaking work resulting from collaborations with both Longboard Pharmaceuticals and UCB, focusing on advancing understanding of sleep disturbances in individuals with Lennox-Gastaut Syndrome (LGS) and their caregivers.
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for ObesityBOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational neurodiagnostics, today announced a strategic collaboration with Skye Bioscience, Inc. (Nasdaq: SKYE), a pharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, to enhance its upcoming CBEYOND™ Phase 2 clinical trial of Nimacimab. This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform and the FDA 510(k)-cleared Dreem 3S EEG device to better understand the comprehensive impact of Nimacimab on patients with obesity.
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related ConditionsCollaboration will initially focus on the role of sleep endpoints in clinical trials relating to rare epilepsy syndromes
Beacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep DisordersCollaboration leverages Beacon’s FDA-cleared at-home EEG headband and artificial intelligence platform to support development of novel precision therapies and improve the diagnostic journey for patients
